- Home
- AQB vs ENVB Comparison
AQB vs ENVB Comparison
Compare AQB & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AQB | ENVB |
|---|---|---|
| Founded | 1991 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.0M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AQB | ENVB |
|---|---|---|
| Price | $0.99 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 24.6K | ★ 266.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,472,659.00 | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.56 |
| 52 Week High | $2.95 | $13.25 |
Technical Indicators
Market Signals| Indicator | AQB | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 36.65 |
| Support Level | $0.87 | $1.96 |
| Resistance Level | $1.10 | $4.29 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 51.78 | 33.33 |
Price Performance
Historical ComparisonAbout AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.